Results of multivariate analysis of age, cytogenetic risk group, and either p53 mutations or combined p53 mutations or 17p-LOH on overall survival in AML
| Variable . | All-treatment group . | Intensive-treatment group . | ||||
|---|---|---|---|---|---|---|
| Hazard ratio . | CI . | P . | Hazard ratio . | CI . | P . | |
| Age ≥ 60 vs < 60 | 3.11 | 1.88-5.15 | < .01 | 3.22 | 1.86-5.56 | < .01 |
| Cytogenetics risk group unfavorable vs not | 2.29 | 1.29-4.07 | < .01 | 2.15 | 1.12-4.11 | .02 |
| P53 exon 2-9 mutations present* vs not | 2.75 | 1.38-5.45 | < .01 | 3.23 | 1.44-7.24 | < .01 |
| Age ≥ 60 vs < 60 | 3.16 | 1.91-5.25 | < .01 | 3.29 | 1.9-5.7 | < .01 |
| Cytogenetics risk group unfavorable vs not | 2.09 | 1.13-3.87 | .02 | 2.07 | 1.05-4.08 | .03 |
| p53 exon 2-9 mutations or 17p LOH (with and without copy loss)† vs not | 2.72 | 1.35-5.47 | < .01 | 2.84 | 1.26-6.4 | .01 |
| Variable . | All-treatment group . | Intensive-treatment group . | ||||
|---|---|---|---|---|---|---|
| Hazard ratio . | CI . | P . | Hazard ratio . | CI . | P . | |
| Age ≥ 60 vs < 60 | 3.11 | 1.88-5.15 | < .01 | 3.22 | 1.86-5.56 | < .01 |
| Cytogenetics risk group unfavorable vs not | 2.29 | 1.29-4.07 | < .01 | 2.15 | 1.12-4.11 | .02 |
| P53 exon 2-9 mutations present* vs not | 2.75 | 1.38-5.45 | < .01 | 3.23 | 1.44-7.24 | < .01 |
| Age ≥ 60 vs < 60 | 3.16 | 1.91-5.25 | < .01 | 3.29 | 1.9-5.7 | < .01 |
| Cytogenetics risk group unfavorable vs not | 2.09 | 1.13-3.87 | .02 | 2.07 | 1.05-4.08 | .03 |
| p53 exon 2-9 mutations or 17p LOH (with and without copy loss)† vs not | 2.72 | 1.35-5.47 | < .01 | 2.84 | 1.26-6.4 | .01 |